Parameter
| Biomarker | BNP/NT-proBNP | Full name | Brain natriuretic peptide / N-terminal pro-brain natriuretic peptide | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | BNP: ~4 kDa; NT-proBNP: ~10 kDa | Core Functional Dimensions | Diagnosis, prognosis, and treatment monitoring | |
| Disease | Heart failure | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Plasma (ELISA and chemiluminescence method, POCT) | ||
| Pathobiological Mechanisms | Ventricular wall pressure/volume load increases trigger myocardial cells release, by activating NPR-A receptor to adjust water sodium excretion, vasodilation, antagonism RAAS system | ||||
| Clinical Availability Status | Clinical available/strong guidelines recommend: ESC/AHA guidelines (2021/2022) as HF diagnosis "Ⅰ class recommended", eliminate HF cutoff: BNP < 100 pg/ml, NT-proBNP < 300 pg/ml; NT-proBNP should be adjusted according to age in acute HF (<55 years >450pg/ml, 55-75 years >900pg/ml, >75 years >1800pg/ml) | ||||
| Notes and Dynamics | The half-life of NT-proBNP (90-120min) is longer than that of BNP (20min), and the plasma stability of NT-proBNP is better, which is more suitable for long-term monitoring of chronic HF. Obese patients (BMI>30kg/m²) need to reduce the cutoff to avoid false negative results. In conjunction with sacubitril/valsartan, degradation by pharmacological inhibition of the BNP, preferred the NT-proBNP curative effect evaluation | ||||